Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Markham, Ontario-based Canadian cannabis producer MedReleaf (TSX: LEAF) announced it will introduce to physicians a patent-pending genetic testing product called ReleafDxTM to help them prescribe cannabis with greater accuracy for each patient. MedReleaf will partner with DynaCare to make this service available to physicians across Canada.

Medical cannabis usage is growing quickly in Canada. There were approximately 75,000 Canadians registered to purchase medical cannabis from a licensed producer in June 2016. That grew to over 200,000 a year later. However, the physician community is looking for more scientific evidence from which to base prescriptions, including strain and dose recommendations.

ReleafDxTM analyzes a patient’s DNA and health conditions to help physicians answer what dosage should be prescribed; and what cannabis product might work best for each person. Specifically, it analyzes biomarkers within metabolic pathways to help identify patients might metabolize cannabis more slowly or quickly than normal. This information will help minimize the chance of adverse reactions and maximize the likelihood of positive effects.

Dynacare, a LabCorp company, will manage the sample analysis and results reporting.  They offer the largest menu of diagnostic tests in Canada and is one of Canada’s largest certified genetic testing laboratories. The test is conducted with a cheek swab in the doctors’ office or at one of over 200 Dynacare Laboratory and Health Services Centers across Canada.

The stock rose p 4.39% on the news to US$12.87. It is up 90% in the last 6 months.

Source: MedReleaf